Antitumor and immunomodulatory effects of low-dose 5-FU on hepatoma 22 tumor-bearing mice

Oncology Letters

Volumn 7, Issue 4, 2014, Pages 1260-1264

  Cao, Zhiyun ^a   Zhang, Zhideng ^b   Huang, Zhengrong ^c   Wang, Rongping ^c   Yang, Ailian ^c   Liao, Lianming ^a   Du, Jian ^a,d  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Fujian Key Laboratory for Technology Research of Inspection and Quarantine   (China)

^c FUJIAN PROVINCIAL CANCER HOSPITAL   (China)

^d Internal Medicine of Second People's Hospital of Fujian Province   (China)

Author keywords

5 FU; Antitumor; Immunomodulatory; Mice

Indexed keywords

FLUOROURACIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DIET; FLOW CYTOMETRY; FOOD INTAKE; IMMUNOMODULATION; LIVER CELL CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE COUNT; MEDICAL PARAMETERS; MOUSE; NATURAL KILLER CELL; NONHUMAN; SPLEEN INDEX; THYMUS INDEX; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

EID: 84896732460     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1856     Document Type: Article

References (23)

1. Mackall CL: T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem cells 18: 10-18, 2000.
2. Cao Y, Zhao J, Yang Z, et al: CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin Immunol 136: 21-29, 2010.
3. Boehm IB, Boehm GA and Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 18: 59-62, 1998.
4. Castano AP, Mroz P, Wu MX and Hamblin MR: Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci USA 105: 5495-5500, 2008.
5. Casale F, Canaparo R, Serpe L, et al: Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 50: 173-179, 2004.
6. Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. NCI Monogr 5: 193-198, 1987.
7. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and flourouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808-815, 1997.
8. Schmoll HJ, Köhne CH and Lorenz M: Weekly 24h infusion of high dose (HD) 5-fluorouracil (FU24h) with or without folinic acid (FA) vs. bolus FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): a randomized Phase III study of the a randomized Phase III study of the EORTC GUTCCG and the AIO. Proc Am Soc Clin Oncol 19: 241a, 2000.
9. Grem JL, McAtee N, Steinberg SM, et al: A phase I study of continuous infusion 5-fluoruuracil plus calcium leucovorin in combination with N-(phosphonoacetyl)-L aspartate in metastatic gastrointestinal adenocarcinoma. Cancer Res 53: 4828-4836, 1993.
10. Hodi FS, Catalano P, Macdonald JS, et al: Age as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Pending submission, 2nd International Conference on Gastrointestinal Oncology, Cologne, Germany, 1996.
11. No authors listed: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 16: 3537-3541, 1998.
12. Garg MB, Sevester JC, Sakoff JA and Ackland SP: Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-flurouracil toxicity. J Chromatogr B Analyt Technol Biomed Life Sci 774: 223-230, 2002.
13. Vetvicka V, Kincade PW and Witte PL: Effects of 5-fluorouracil on B lymphocyte lineage cells. J Immunol 137: 2405-2410, 1986.
14. Kobayashi R, Yoshimatsu K, Ishibashi K, Yokomizo H, Umehara A, Yoshida K, Fujimoto T, Watanabe K and Ogawa K: Host immunity in colorectal cancer patients treated with low-dose Leucovorin plus 5-fluorouracil. Gan To Kagaku Ryoho 31: 1783-1785, 2004 (In Japanese).
15. Kobayashi R, Yoshimatsu K, Yokomizo H, Katsube T and Ogawa K: Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity. Anticancer Res 27: 675-679, 2007.
16. Codacci-Pisanelli G, van der Wilt CL, Pinedo HM, Franchi F, Noordhuis P, Braakhuis B, van Laar JA and Peters GJ: Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice. Eur J Cancer 31A: 1517-1525, 1995.
17. Vichaya EG, Cook JL, Frazier MA, Young EE and Meagher MW: Modeling symptoms of chemotherapy: Bortezomib and 5-fluorouracil induce sickness in mice. Brain Behav Immun 24: 6-7, 2011.
18. Young SD, Whissell M, Noble JC, Cano PO, Lopez PG and Germond CJ: Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 12: 3092-3098, 2006.
19. Awwad M and North RJ: Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 49: 1649-1654, 1989.
20. Berd D and Mastrangelo MJ: Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 47: 3317-3321, 1987.
21. Shen FZ, Wang J, Liang J, Mu K, Hou JY and Wang YT: Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells? Int J Exp Pathol 91: 10-16, 2010.
22. Pasquier E, Kavallaris M and André N: Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7: 455-465, 2010.
23. Zhu Q, Liu JY, Yang CM, Xu HW, Zhang AZ, Cui Y, Wang HB, Qin CY and Li YQ: Influence of antitumor drugs on the expression of Fas systemin SW480 colon cancer cells. Eur J Gastroenterol Hepatol 18: 1071-1077, 2006.